Regulatory Due Diligence for Biotech Acquisitions

This case study outlines the regulatory due diligence process conducted by ProPharma Group for a client involved in a biotech acquisition. The objective was to identify both critical and minor risks associated with the acquisition of a company that had filed a New Drug Application (NDA) with the FDA and a Marketing Authorization Application (MAA) with the EMA. ProPharma mobilized a team of consultants to assess the viability of the target company's regulatory submissions and potential commercialization issues. The due diligence report detailed findings categorized as critical, major, and minor, with critical issues communicated immediately to facilitate timely decision-making. The study emphasizes the importance of a thorough due diligence process to uncover hidden risks and ensure informed investment decisions. The successful completion of the due diligence allowed the client to proceed with the acquisition confidently, and ProPharma continued to assist with regulatory integration post-acquisition.